Search clinical trials for: HIV Therapeutic vaccine

Total 33454 results

National Institute of Allergy and Infectious Diseases...

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

HIV

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
University of Sao Paulo General Hospital

Not yet recruiting

Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals

HIV Vaccine

Brazil
Soleno Therapeutics, Inc.

Not yet recruiting

An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

SH2B1 Deficiency Obesity | Obesity Associated With PCSK1 Mutation (rs6232 Variant) | SIM1 Deficiency Obesity
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States
IrsiCaixa
Hospital Clinic of Barcelona; University of Oxford; Germans Trias i Pujol Hospital and other collaborators

Completed

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

HIV

Spain
Washington University School of Medicine
COVID -19 Therapeutics Accelerator

Completed

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION (CROWN CORONA)

COVID 19

United States, South Africa, Ghana, United Kingdom, Zambia
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

HIV Infections

Brazil, United States, South Africa, Peru, Thailand, Argentina, Vietnam
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC; Inovio Pharmaceuticals

Active, not recruiting

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Anal Intraepithelial Neoplasia | High Grade Squamous Intraepithelial Neoplasia | HIV Positivity | Human Papillomavirus-16 Positive | Human Papillomavirus-18 Positive

United States, Puerto Rico
Shenzhen Immuno Cure Biomedical Company Limited
Shenzhen Third People's Hospital

Active, not recruiting

ICVAX as a HIV Therapeutic DNA Vaccine

Human Immunodeficiency Virus | Human Immunodeficiency Virus I Infection

China
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

HIV Infections | Cytomegalovirus Infections | Vaccine

United States
Sharon Riddler
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (DC-HIV04)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
Aelix Therapeutics
Gilead Sciences

Completed

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients (AELIX-003)

HIV/AIDS

Spain
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); AIDS Clinical... and other collaborators

Active, not recruiting

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

HIV Infection

United States, Peru, Brazil
Steven Deeks
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

Therapeutic Vaccination in Treated HIV Disease

HIV-1-infection

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Aelix Therapeutics

Completed

Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)

HIV-1 Infection

Spain
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
National Institute of Dental and Craniofacial Research (NIDCR)

Completed

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

HIV Infections | Sexually Transmitted Diseases

United States, Puerto Rico, South Africa, Brazil
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Merck Sharp & Dohme LLC; Adult AIDS Clinical Trials Group

Completed

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

HIV Infections | Herpes Zoster

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Glaxo Wellcome

Completed

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; MicroGeneSys Inc (nka Protein Sciences Corporation)

Completed

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

HIV Infections

United States, Puerto Rico, Brazil
National Institute of Allergy and Infectious Diseases...

Completed

Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Withdrawn

Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; Acute Infection and Early Disease Research Program

Completed

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

HIV Infections

United States, American Samoa, Australia
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy | HIV Seronegativity
National Institute of Allergy and Infectious Diseases...

Completed

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Withdrawn

Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults

HIV Infections
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

HIV Infections | HIV Seronegativity

Search clinical trials for: HIV Therapeutic vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations